baber/WOPTO huggingface dataset:
Patent NZ-598808-A (NZ)
Title: Pi3 kinase inhibitors and uses thereof
Inventor: NIU DEQIANG
IPC: C12N9/12
Filed: 2010-09-09
Abstract: Disclosed are conjugates of one or more PI3 kinases having a cysteine residue, CysX, wherein the CysX is covalently, and irreversibly, bonded to a PI3 kinase inhibitor, wherein CysX is selected from Cys862 of PI3K-alpha, Cys2243 of MTOR, Cys838 of PI3K-alpha, Cys869 of PI3K-gamma, Cys815 of PI3K-delta, Cys841 of PI3K-beta, Class 1A, Cys 1119 of PI3K-beta, Class 2, Cys3683 of DNA-PK, Cys2770 of ATM-Kinase, Cys2753 of ATM-Kinase, Cys 1840 of PI4KA, Cys 1844 ofPI4KA, or Cysl797 of PI4KA. The compounds are PI3 Kinase inhibitors and are sometimes conjugated to a peptide sequence. In particular the kinase inhibitors are compounds of formula (II-i).
Patent NZ-599608-A (NZ)
Title: Mask vent
Inventor: NG EVA
IPC: A61M16/06
Filed: 2008-08-25
Abstract: 599608 Apparatus for providing positive airway pressure therapy to the airways of a patient, comprising: a mask; a gas delivery conduit coupled to the mask; and a vent located in the mask or near the mask in the gas delivery conduit, to allow washout of exhaled carbon dioxide. The vent comprises a plurality of vent orifices (2006, 2008). The vent orifices are constructed and arranged to be open in use at least during the inhalation and exhalation phases of the user's breathing cycle. The vent orifices are molded into a curved surface so that a vent flow from each of the orifices is directed in different directions, into one another, and/or slightly offset from one another to create diffuse air flow.
Patent NZ-601779-A (NZ)
Title: The use of sodium dodecylbenzene sulphonate for combating stains from a dental surface
Inventor: AITKEN GAIL CAMERON
IPC: A61Q11/00
Filed: 2011-03-22
Abstract: Disclosed herein is the use of sodium dodecylbenzene sulphonate (SDDBS) for helping to prevent or remove surface deposited stains from natural teeth and dental prostheses and oral care compositions comprising SDDBS for such use. The compositions optionally further comprise a source of zinc ions such as zinc chloride and/or 4-isopropyl-3-methylphenol (IPMP).
Patent NZ-606454-A (NZ)
Title: Wind energy installation working gantry and wind energy installation
Inventor: Müller Johann
IPC: F03D11/00
Filed: 2011-06-20
Abstract: Disclosed is a locking device for closing off a movable railing (7) on a working platform (3). The movable railing is arranged in a transfer region (25) to a lift (27). Opening of the movable railing allows workers to move between the lift and the working platform. The locking device comprises a locking mechanism (9) for locking and unlocking the movable railing. A first locking element (29) is connected to the lift. A second locking element (15) is connected to the movable railing. The locking mechanism is adapted to release one of the two locking elements by means of locking of the respective other locking element. This is such that at any one time, one of the first locking element, which is connected to the lift, or the second locking element, which is connected to the movable railing, is engaged with the locking mechanism (see figures 2, 4 & 5). This reduces the risk of workers accidentally falling in the transfer region, due to absence of the lift, or due to a movable railing being left open or unlocked.
Patent NZ-613356-A (NZ)
Title: Crystalline anti-htnfalpha antibodies
Inventor: BORHANI DAVID W
IPC: G01N31/00
Filed: 2007-10-25
Abstract: Disclosed is a batch crystallisation method for crystallising an anti-hTNFalpha antibody, comprising the steps of: (a) providing an aqueous solution of said antibody in admixture with an inorganic phosphate salt as crystallisation agent to obtain an aqueous crystallisation mixture, wherein the aqueous crystallisation mixture has a pH of about 3 to about 5; and (b) incubating said aqueous crystallisation mixture until crystals of said antibody are formed, wherein the anti-hTNFalpha antibody is an IgG human anti-hTNFalpha antibody comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:2, wherein said crystal has a needle morphology with a length of about 2-500 μm and an l/d ratio of about 3 to 30, wherein said sequences are as defined in the complete specification.
Patent NZ-617334-A (NZ)
Title: Cyclopropyl amine derivatives
Inventor: LIU HUAQING
IPC: C07D495/04
Filed: 2008-12-05
Abstract: Disclosed herein is the compound (S)-3-hydroxy-1-(4-((1S,2S)-2-(((S)-2-methylpyrrolidin-1-yl)methyl)cyclopropyl)phenyl)pyrrolidin-2-one or a pharmaceutically acceptable salt, ester, or amide thereof. Also disclosed is the use of (S)-3-hydroxy-1-(4-((1S,2S)-2-(((S)-2-methylpyrrolidin-1-yl)methyl)cyclopropyl)phenyl)pyrrolidin-2-one in the manufacture of a medicament for treating a disease such as attention-deficit hyperactivity, Alzheimer’s disease, dementia, a condition or disorder affecting schizophrenia, cognitive deficits of schizophrenia, a condition or disorder affecting narcolepsy, sleep disorders, allergic rhinitis, asthma, or obesity. Also disclosed is the use of pharmaceutical compositions comprising (S)-3-hydroxy-1-(4-((1S,2S)-2-(((S)-2-methylpyrrolidin-1-yl)methyl)cyclopropyl)phenyl)pyrrolidin-2-one or a crystalline polymorph of the compound 2-{ 4-[(1S,2S)-2-((S)-2-methyl-pyrrolidin-1-ylmethyl)-cyclopropyl]-phenyl} -2H-pyridazin-3-one, in the manufacture of medicaments for the treatment of conditions modulated by histamine-3 (H3) receptor as described above.
Patent NZ-617581-A (NZ)
Title: Radiolabelled glutaminyl cyclase inhibitors
Inventor: DEMUTH HANS-ULRICH
IPC: C07D233/70
Filed: 2012-05-24
Abstract: The disclosure relates to radiolabelled imidazole glutaminyl cyclase (QC) inhibitors for use as imaging agents. The disclosure also relates to pharmaceutical compositions comprising these compounds and the use of these compounds for imaging and detection in neurological disorders, such as Alzheimer’s disease, Familial British Dementia, Familial Danish Dementia, Down Syndrome and Huntington’s disease.
Patent NZ-618124-A (NZ)
Title: Picture gesture authentication
Inventor: JOHNSON JEFF
IPC: G06F3/01
Filed: 2011-10-09
Abstract: A picture signature password system is disclosed. The system may use a picture signature password to determine access to a computing device or service. A display screen may display a personalized digital image. A user input device may receive a user drawing set executed by a user over the personalized digital image, associating a user drawing set member with a 5 user position set; associating a library drawing set member with a library position set; determining the user drawing set member and the library drawing set member match in part if the user position set is within a position tolerance value of the library position set. A processor may authenticate access to the user session if the user drawing set matches a library drawing set associated with the user.
Patent NZ-631569-A (NZ)
Title: Phenyl alkanoic acid derivatives as gpr agonists
Inventor: KUMAR SANJAY
IPC: C07D405/12
Filed: 2013-02-27
Abstract: Disclosed are 2-(3-(phenyl)oxetan-3-yl)acetic acid, 2-(3-(phenyl)azetidin-3-yl) acetic acid derivatives and alkyl esters thereof as represented by general formula (I), wherein, R1 is hydrogen or alkyl; R2 and R3 together form a saturated or a partially unsaturated 3- to 9-membered heterocyclyl ring containing one or two heteroatoms selected from the group consisting of O, N and S; or R2 and R3 together form a saturated or a partially unsaturated cycloalkyl ring; R4 at each occurrence is independently selected from the group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, aryl, -NH2, cyano, nitro, -C(O)R9 and -S(O)pR6; Rx and Ry are independently selected from the group consisting of A-CH(R7)-X and R5; provided that at least one of Rx and Ry is A-CH(R7)-X; n is an integer from 1 to 3; m is an integer from 0 to 4; and wherein the remaining substituents are as defined herein. Representative compounds include ethyl 2-(3-(4-((4’-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)oxetan-3-yl)acetate, 2-(3-(4-([1,1’-biphenyl]-3-ylmethoxy)phenyl)oxetan-3-yl)acetic acid, ethyl 2-(3-(4-((2’,6’-dimethyl-4’-(3-(methylsulfonyl)propoxy)-[1,1’-biphenyl]-3-yl)methoxy)-3-fluorophenyl)oxetan-3-yl)acetate, ethyl 2-(3-(4-((2’,6’-dimethyl-4’-((tetrahydrofuran-2-yl)methoxy)-[1,1’-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate, 2-(3-(4-((4’-((1,3-difluoropropan-2-yl)oxy)-2’,6’-dimethyl-[1,1’-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetic acid, 2-(1-acetyl-3-(4-((2’,6’-dimethyl-4’-(3-(methylsulfonyl)propoxy)-[1,1’-biphenyl]-3-yl)methoxy)phenyl)azetidin-3-yl)acetic acid and ethyl 2-(3-(4-((2’,6’-dimethyl-4’-(3-(methylsulfonyl) propoxy)-[1,1’-biphenyl]-3-yl)methoxy)phenyl)azetidin-3-yl) acetate. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above, or an isotopic form or a stereoisomer or a tautomer or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable excipient for the treatment of a disease or a condition mediated by GPR40, such as selected from the group consisting of diabetes, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglylceridemia, dyslipidemia, metabolic syndrome, cardiovascular disease, atherosclerosis, kidney disease, polycystic ovary syndrome, ketoacidosis, thrombotic disorders, nephropathy, diabetic neuropathy, diabetic retinopathy, sexual dysfunction, fatty liver development, dermatopathy, dyspepsia, hypoglycemia, cancer, edema and pancreatic beta cell degeneration.
Patent NZ-711355-A (NZ)
Title: Anti-lag-3 binding proteins
Inventor: HAMBLIN PAUL ANDREW
IPC: C07K16/28
Filed: 2014-03-13
Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells are provided. Further provided is the use of said antigen binding proteins in the treatment and/or prevention of diseases associated with the involvement of pathogenic T cells for example auto-immune diseases, such as psoriasis, Crohn’s disease, rheumatoid arthritis, primary biliary cirrhosis, systemic lupus erythematosus (SLE), Sjögren’s syndrome, multiple sclerosis, ulcerative colitis and autoimmune hepatitis; infectious diseases, allergic diseases and cancer.
Patent NZ-722551-A (NZ)
Title: System and method for concentrating gas
Inventor: RICHEY II JOSEPH B
IPC: C01B21/04
Filed: 2013-03-08
Abstract: A system for purifying or filtering air or gas to capture increased oxygen content is described. The system uses a controller that reads data from one or more sensors to optimise the timing of expulsion or intake of air or gas to be processed. The system includes one or more separation beds (310, 312) for adsorption of nitrogen or other gas, valves controlling intake of external gas (332, 336), one or more sensors (352) and a controller (350) that uses information from the sensor/s to determine when the separation bed is full, when to equalise the pressure between multiple separation beds etc.
Patent NZ-724100-A (NZ)
Title: Compositions for modulating sod-1 expression
Inventor: FREIER SUSAN
IPC: A61P25/28
Filed: 2015-04-01
Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
Patent NZ-736250-A (NZ)
Title: Apparatus and methods for ventilatory treatment
Inventor: BASSIN DAVID
IPC: A61M16/00
Filed: 2013-04-12
Abstract: Disclosed is an apparatus for treating a respiratory disorder. The apparatus is configured to compute a duration of a detected episode of apnea or hypopnea, and adjust a value of expiratory positive airway pressure (EPAP) according to the computed duration, such that with increasing duration, the adjusted value of EPAP exponentially approaches a value that is greater than a maximum EPAP value.
Patent NZ-753142-A (NZ)
Title: Inhibitors of glucocorticoid receptor
Inventor: DU XIAOHUI
IPC: C07J51/00
Filed: 2017-10-06
Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein is a substituted steroidal derivative compound of the formula depicted, and pharmaceutical compositions comprising said compound. The subject compound and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
Patent NZ-754695-A (NZ)
Title: Infusion pump system and method with multiple drug library editor source capability
Inventor: JACOBSON JAMES D
IPC: G16H40/00
Filed: 2016-05-16
Abstract: No infusion pump is presently available which is able to obtain drug libraries from different types of drug library editors, e.g., from both dedicated DLEs and enterprise DLEs. Although in the case of enterprise DLEs, one OLE may be used with different types of infusion pumps, no infusion pump can receive drug libraries from more than one OLE even though one infusion pump type can be used in different settings, such as the home or hospital. In present practice, one infusion pump can receive a drug library from one specified type of drug library editor, but no other. For example, one infusion pump can receive a drug library from an enterprise drug library editor, but not a dedicated drug library editor. Similarly, a different kind of infusion pump can receive a drug library from a dedicated drug library editor, but not an enterprise drug library editor. Thus, the manufacturer must produce and the users must select different infusion pumps and associated DLEs for different applications, increasing cost and complexity. Different programming is required for dedicated DLEs and enterprise DLEs, increasing the confusion and effort required for programmers of different DLEs. Healthcare systems which cover multiple levels of care from home care to hospital care must maintain different DLEs for different levels, increasing costs to the healthcare system and to the consumers. Accordingly, the present invention provides an infusion pump system and method with multiple drug library editor source capability including: an infusion pump system having a first drug library editor operable to generate a first drug library; a second drug library editor operable to generate a second drug library; and an infusion pump configured to connect with the first drug library editor and the second drug library editor, the first drug library editor different than the second drug library editor. The infusion pump having an operational drug library for use during operation of the infusion pump, said operational drug library can be selected from one of the first drug library received from the first drug library editor and the second drug library received from the second drug library editor. The first drug library editor is a dedicated drug library editor, and the second drug library editor is the enterprise drug library editor. The infusion pump is configured to identify whether the operational drug library comes from the first drug library editor or the second drug library editor based on a configuration setting.
Patent NZ-762665-A (NZ)
Title: Laminate structure for biocompatible barrier packaging
Inventor: VON KIRCHBACH HANS PAUL HENNING
IPC: B32B27/08
Filed: 2018-10-04
Abstract: Biocompatible flexible laminate structure comprising an alternating stack of layers from polymers A and B or polymer blends AC and BD having the sequence -A-[B-A-]n- or AC-[BD-AC-]nwith n from 4 to 36, wherein the layer thickness of layers A or AC and layers B or BD is less than 3 µm, wherein A and B are thermoplastic polymers and C and D are thermoplastic elastomers, at least part of the monomeric building blocks of polymer A, B or A and B are from renewable sources wherein the thermoplastic polymer B has functional barrier properties, wherein the amount of the thermoplastic elastomers C and D in the polymer blends AC and BD is each from 3 to 45 wt.-%, and polymer B and elastomer D are essentially incompatible.
Patent NZ-766920-A (NZ)
Title: An optical fiber ribbon and a method and system of producing the same
Inventor: FALLAHMOHAMMADI EHSAN
IPC: G02B6/44
Filed: 2018-01-15
Abstract: The present invention relates to an optical fiber ribbon, comprising a plurality of adjacent optical fiber units extending in a longitudinal direction and arranged in parallel forming an optical fiber assembly having a width, each of the optical fiber units comprising either a single fiber or a group of at most three optical fibers, preferably two optical fibers, encapsulated with a matrix material; and a plurality of successive elongated rectilinear beads of a bonding material being arranged along a length of said assembly; each of said plurality of beads being configured to form an elongated bond between two adjacent optical fiber units of the plurality of optical fiber units; wherein a first bead forming a first bond connects a first pair of adjacent optical fiber units while the successive bond formed by the successive bead, connects a further pair of adjacent optical fiber units, wherein at least one optical fiber unit of the further pair differs from the optical fiber units of the first pair. The present invention moreover relates to a method of producing such an optical fiber ribbon. A fluorescent tracer is present in the beads. The fluorescent tracer has an absorption region that differs from the absorption region of a UV curing photoinitiator(s).
Patent PT-103543-A (PT)
Title: Vacina meningocócica polissacárida do serogrupo c conjugada com uma proteína tranportadora recombinante p64k
Inventor: VIEIRA MARGARIDA SOFIA RAFAEL
IPC: A61K39/095
Filed: 2006-07-28
Abstract: A PRESENTE INVENÇÃO CONSISTE NA PRODUÇÃO DE UMA VACINA MENINGOCÓCICA CONJUGADA COM UMA PROTEÍNA RECOMBINANTE (P64K) DE NEISSERIA MENINGITIDIS. ESTA PROTEÍNA FORTEMENTE IMUNOGÉNICA TRANSPORTA O POLISSACÁRIDO ESPECÍFICO PARA O SEROGRUPO C, ESTE É RECONHECIDO EFICIENTEMENTE. A PRESENTE INVENÇÃO TRATA DE UMA VACINA MAIS IMUNOGÉNICA E EFECTIVA RELATIVAMENTE ÀS EXISTENTES, PODENDO SER USADA COM SEGURANÇA EM CRIANÇAS A PARTIR DOS DOIS MESES E ADULTOS. A PRODUÇÃO É REALIZADA RECORRENDO A DOIS PROCESSOS: PRODUÇÃO DA PROTEÍNA RECOMBINANTE E DO POLISSACÁRÍDO, SENDO O RESULTADO DA CONJUGAÇÃO DESTES DOIS PRODUTOS A VACINA FINAL. A PRESENTE INVENÇÃO É DE FÁCIL IMPLEMENTAÇÃO A NÍVEL INDUSTRIAL, A MATÉRIA-PRIMA E REAGENTES SÃO DE FÁCIL AQUISIÇÃO E CUSTO REDUZIDO. OS EQUIPAMENTOS NECESSÁRIOS SÃO DE TAMANHO REDUZIDO, O RETORNO FINANCEIRO DA APLICAÇÃO É RÁPIDO. A ÁREA NECESSÁRIA PARA A PRODUÇÃO É REDUZIDA COMPARATIVAMENTE A OUTRO TIPO DE INDÚSTRIAS FARMACÊUTICAS. OS EFLUENTES RESULTANTES TÊM VOLUME REDUZIDO E O TRATAMENTO É CONTROLADO.
Patent PT-104477-A (PT)
Title: Sistema de montagem, bloqueamento e desmontagem deinvólucros para garrafas de gás
Inventor: PINTO CARLOS ALBERTO FERREIRA AGUIAR
IPC: B01L3/12
Filed: 2009-03-26
Abstract: SISTEMA DE MONTAGEM, BLOQUEAMENTO E DESMONTAGEM DEINVÓLUCROS PARA GARRAFAS DE GÁS DE NATUREZA MODULAR EINTERMUTÁVEL, QUE PERMITE A SUA ABERTURA PARA INSPECÇÃO OU SUBSTITUIÇÃO DE COMPONENTES SEM DESTRUIÇÃO RELEVANTE DE NENHUMA DAS PARTES. A SOLUÇÃO DECORRE DA CONCEPÇÃO DE UMA BASE (1) QUE RECEBE ORESERVATÓRIO (2), NA QUAL É MONTADO UM DISCO INTERIOR (3)ATRAVÉS DE UM SISTEMA DE ENCAIXE MACHO FÊMEA, SENDO ESTE BLOQUEADO APÓS A SUA ROTAÇÃO. O CARÁCTER NÃO DESMONTÁVEL DESTE CONJUNTO É OBTIDO ATRAVÉS DE UM BLOQUEADOR (4),TRAVADO ATRAVÉS DA FIXAÇÃO DAS PEGAS SIMÉTRICAS (5), SENDO REFORÇADA A SUA GARANTIA DE ESTABILIDADE PELA UTILIZAÇÃO DE UM PINO DE SEGURANÇA (6). COM ESTE SISTEMA CONSEGUEM-SE VANTAGENS AO NÍVEL DA ECONOMIA DE RECURSOS, RECICLAGEM SELECTIVA, OPTIMIZAÇÃO ESTRUTURAL E SEGURANÇA PELA DIFERENCIAÇÃO DE PRODUTOS CONTIDOS NA EMBALAGEM ATRAVÉS DO USO DE CORES DE IDENTIFICAÇÃO.
Patent PT-105054-A (PT)
Title: Equipamento de defesa pessoal munido de dispositivo angular de libertação de líquidos e gases pressurizados com amortecedor de impacto frontal.
Inventor: LOPES FERNANDO JORGE MALDONADO FERREIRA
IPC: F41H9/00
Filed: 2010-04-16
Abstract: EQUIPAMENTO DE DEFESA PESSOAL MUNIDO DE DISPOSITIVO ANGULAR DE LIBERTAÇÃO DE LÍQUIDOS E GASES PRESSURIZADOS COM AMORTECEDOR DE IMPACTO FRONTAL QUE COMPREENDE UM CORPO PRINCIPAL (2) DOTADO DE UMA PEÇA CONSTITUÍDA PELO BOTÃO DE PRESSÃO (1A) E UM ÊMBOLO ACCIONADOR (1C) NO EXTREMO OPOSTO DA PRÓPRIA PEÇA (1) ONDE ESTÁ INSERIDO NUM CAVADO (23) O ROLETE (14), ASSIM, AO SER PRESSIONADO O BOTÃO EXTERIOR (1A) O ÊMBOLO ACCIONADOR (1C) COMPRIME ATRAVÉS DO ROLETE (14) UMA SUPERFÍCIE (13) EM FORMA DE CUNHA SITUADA NO EXTREMO BISELADO DO EMBOLO COMPRESSOR (3) COMPRIMINDO ESTE ATRAVÉS DO SEU DESLOCAMENTO LONGITUDINAL UMA MOLA (10); ÊMBOLO COMPRESSOR (3) ESSE QUE SE DESLOCA GUIADO PELA PEÇA GUIA (9) E EMPURRA A BASE (35) DE UMA BOTIJA DE GÁS QUE AO DESLOCAR-SE COMPRIME UMA VÁLVULA DE LIBERTAÇÃO DE LÍQUIDOS OU GASES (36) LIBERTANDO-SE O REFERIDO FLUIDO PRESSURIZADO ATRAVÉS DE FURO (7) LOCALIZADO NA TAMPA (18); O REFERIDO CORPO PRINCIPAL (2) PODERÁ TER ACOPLADO UM BASTÃO OU PEGA (44) ONDE É INCORPORADO UM MECANISMO DE AMORTECIMENTO DE IMPACTO FRONTAL, CONSTITUÍDO POR UMA TAMPA (42) OU EMBOLO INTERNO (53) QUE ABSORVEM ENERGIA ATRAVÉS DE MOLA DE AMORTECIMENTO (43).
Patent RU-94015469-A (RU)
Inventor: SHAROV A.N. SHAROV A N
IPC: H04L27/14
Filed: 1994-04-26
Abstract: FIELD: devices for reception and processing of digital information. SUBSTANCE: adaptive generation of weights in weight calculation unit is performed using short-time estimation in required time moments using time sequences of random noise using analysis of previous history of process to be predicted. Prediction of levels of random noise for each frequency is done using previous process behavior till moment T. Averaged level of random noise is read from output of integrator which integration time is equal to τ. Correlation function for sequences of average levels of noise along frequency axis provides loose correlation for intervals DF. This results in usage of weights, which are generated on basis of prediction, for calculation of mix of signal and random noise in sub-channels which bandwidth is overlapped with correlation interval ΔFdepending of bandwidth of band-pass filter in sub-channel. EFFECT: increased stability to noise, simplified design.
Patent RU-94018517-A (RU)
Inventor: KHOAKIN KHUNKERAS GERRE
IPC: B67B3/00
Filed: 1994-05-27
Abstract: FIELD: packing; opening or closing of bottles. SUBSTANCE: sealing head has cap 1 put on cover 7 of bottle 9 and breaking lines 3a, 3b, 3c. Upper end of cap is left open or free and breaking lines 3a, 3b mark tabs which can be torn off from indicated open or free end. Sealing head has skirt 2 and device to provide fastening of head on bottles 9 or similar articles differing in that tabs are located in axial direction and at least one of breaking lines (3b), reaches peripheral line (3c) located between cap 1 and skirt 2. Above indicated tabs form integral portion of cap 1 of head. The latter is made fast on cover 7 of bottle 9 by fixing means of skirt 2 so that, with head 1 separated from bottle, skirt 2 remains connected with skirt 8 of plug 7. This makes it possible to seal and unseal bottles. EFFECT: enlarged operating capabilities. 2 dwg